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Abstract
Background: Francisella tularensis (FT) is a gram-negative facultative intracellular coccobacillus and is the causal
agent of a life-threatening zoonotic disease known as tularemia. Although FT preferentially infects phagocytic cells
of the host, recent evidence suggests that a significant number of bacteria can be found extracellularly in the
plasma fraction of the blood during active infection. This observation suggests that the interaction between FT and
host plasma components may play an important role in survival and dissemination of the bacterium during the
course of infection. Plasminogen (PLG) is a protein zymogen that is found in abundance in the blood of
mammalian hosts. A number of both gram-positive and gram-negative bacterial pathogens have the ability to bind
to PLG, giving them a survival advantage by increasing their ability to penetrate extracellular matrices and cross
tissue barriers.
Results: We show that PLG binds to the surface of FT and that surface-bound PLG can be activated to plasmin in
the presence of tissue PLG activator in vitro. In addition, using Far-Western blotting assays coupled with proteomic
analyses of FT outer membrane preparations, we have identified several putative PLG-binding proteins of FT.
Conclusions: The ability of FT to acquire surface bound PLG that can be activated on its surface may be an
important virulence mechanism that results in an increase in initial infectivity, survival, and/or dissemination of this
bacterium in vivo.
Background
Francisella tularensis (FT) is a Gram-negative intracellu-
lar pathogen that is the etiological agent of a multi-syn-
dromic disease with a high morbidity/mortality that is
referred to as tularemia. The pneumonic form of tulare-
mia is of particular concern because of the high mortal-
ity rate (up to 60%) following inhalation of as few as ten
organisms [1-4]. Francisella species are found through-
out the Northern Hemisphere and infect a variety of
vertebrate and invertebrate hosts [5,6]. Infections with
FT can be contracted from blood sucking insects, such
as the deer fly [5,7], mosquitoes [8,9], and ticks [5,7,10],
and by open-wound contact with infected animal tissue
[5,11,12].
Upon entry into a susceptible vertebrate host, FT is
readily phagocytized by resident macrophages and den-
dritic cells and quickly escapes into the cytoplasm
[13,14] where it multiplies. Late in its replicative cycle,
FT induces apoptotic death of the host phagocyte,
resulting in release of progeny bacteria that can infect
new host cells. Recent studies have shown that signifi-
cant numbers of FT are found in the acellular plasma
fraction of mice infected intradermally or intranasally
with either FT Live Vaccine Strain (LVS) (Type B) or
FT Schu S4 (Type A) [15], and intranasally with FT
novicida [16]. These findings suggest that, in addition to
utilizing the intracellular cytoplasmic niche for replica-
tion and protection from humoral immunity, FT may
also have a significant extracellular phase. Several stu-
dies have shown that deposition of host complement
component C3 on the surface of FT is required for
opsonophagocytosis by activating CR3 and CR4-
mediated phagocytosis by macrophages and dendritic
cells [14,17,18]. It is also known that FT is relatively
resistant to complement-mediated lysis [19]. A recent
report suggested that resistance of FT to membrane
attack complex-mediated lysis may be due (at least in
part) to its ability to bind to factor H from host plasma
[20]. It is possible that the ability of FT to bind to factor
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plays a significant role in its pathogenesis.
It has been long established that a broad spectrum of
both gram-positive and gram-negative bacterial patho-
gens gain a survival advantage by interacting with com-
ponents of the host coagulation/fibrinolytic system in
humans [21-24]. For instance, the ability to acquire sur-
face-associated plasmin has been documented as an
important virulence mechanism in Group A streptococci
[25], Borrelia burgdorferi [26], and Yersinia pestis [27]
by aiding in the organism’s ability to penetrate the
extracellular matrix and to disseminate to distal sites in
the host. Plasminogen (PLG) is a 92-kDa glycoprotein
z y m o g e nt h a ti si n v o l v e di nf i b rinolysis. This precursor
protein is converted to an active serine protease (plas-
min) by cleavage of the peptide bond between residues
R
560and V
561 in vivo v i au r o k i n a s e - t y p e( u P A )a n d / o r
tissue-type (tPA) PLG activators. Plasmin has an impor-
tant role in blood clot resolution because of its role in
the degradation of fibrin polymers. Because plasmin has
other substrates that include pro-collagenases, pro-
metalloproteinases, and extracellular matrix proteins,
such as fibronectin, laminin, and vitronectin, the ability
of a bacterium to acquire surface-associated plasmin can
result in an enhanced ability of the pathogen to pene-
trate the extracellular matrix and to disseminate to dis-
tal sites in the host [21,23,25]. In this report we show
that PLG binds to the surface of FT in vitro and that
surface-bound PLG can be converted to the active plas-
min form. In addition, using a combination of Far-Wes-
tern blotting analyses coupled with proteomic
methodologies, we have identified several FT proteins
that can bind to human PLG in vitro.
Results
Binding of PLG from fresh human plasma to the surface
of FTLVS
We used an ELISA assay to determine that PLG in fresh
frozen plasma (FFP) binds to FTLVS grown to mid-log
phase in BHI (Figure 1). Binding was inhibited when ε-
aminocaproic acid (εACA), known to inhibit binding of
PLG to lysine groups in proteins, was included in the
incubation mixture. To help eliminate the possibility of
non-specific binding of PLG due to its high concentra-
tions in human plasma and also to rule out the contri-
butions of other plasma proteins, we used purified
human Glu-PLG (huPLG) and noted similar results to
those observed when FFP was used (Figure 2A). We
also found that huPLG binds to the highly virulent Schu
S4 strain of FT at moderately higher levels than
observed with FTLVS (Figure 2B). We confirmed that
binding of huPLG to FT is a lysine-dependent interac-
tion by showing that increasing concentrations of εACA
can inhibit binding of huPLG to FTLVS in a dose-
dependent fashion (Figure 3). When similar concentra-
tions of glycine were used as an inhibitor control, no
inhibition of huPLG binding was observed (data not
shown). Confocal microscopic analyses suggested that
huPLG binds to the surface of FT (Figure 4); however, it
is possible that some of the staining observed was the
result of huPLG penetration into the outer envelope of
FT. Although is has been reported that culture media
composition can have a significant impact of the surface
properties and virulence characteristics of FTLVS [28],
we observed no differences in the ability of PLG to bind
to the surface of FTLVS grown in modified Mueller-
Hinton medium vs. brain-heart infusion broth (data not
shown).
Plasmin activation on the surface of FT LVS in vitro by a
PLG activator
In other bacterial systems, surface-bound PLG can be
converted to its proteolytically active plasmin form that
contributes to the organism’s virulence [21-24]. To test
whether huPLG bound to FTLVS can be converted
to plasmin, we used a chromogenic plasmin substrate
Figure 1 FT binds to PLG from human plasma. FTLVS cultured to
mid-log phase in BHI broth were bound to wells of microtiter plates
and then incubated for 1 hour with fresh frozen human plasma
(FFP) in the presence or absence of 100 mM ε-amino caproic acid
(εACA), a PLG-binding inhibitor. A modified ELISA was performed to
measure FTLVS-bound PLG. The results shown are representative of
3 experiments of similar design. Bars indicate +/- SEM in triplicate.
Statistical analysis was performed via one-way ANOVA using a
Dunnett’s Multiple Comparison post-test (*** P < .001).
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Page 2 of 9(H-D-Val-Leu-Lys-pNA) to detect proteolytic activity
following the addition of tissue PLG activator (tPA)
(Figure 5). We also found that plasmin on the surface of
FT can break down fibronectin (Figure 6), suggesting
that FT-bound plasmin can potentially participate in the
degradation of extracellular matrices.
Identification of putative Francisella PLG-binding
membrane proteins
We used Far-Western Blot methodology and mass spec-
trometry to identify potential PLG receptors in the Sar-
kosyl soluble and insoluble FTLVS membrane fractions
(Figure 7). Sarkosyl is a weak anionic detergent in which
many outer membrane proteins of Gram-negative bac-
teria are insoluble [29]. We transferred the Sarkosyl-
treated proteins to a PVDF membrane and incubated
the membrane with PLG and identified bound PLG by
reaction with anti-PLG mAbs (Figure 7a). We used the
relative migration rates of the reactive bands to identify
the reactive proteins on a duplicate Coomassie-stained
polyacrylamide gel (Figure 7b), which were then excised
for proteomic analysis by mass spectrometry. Several
prominent PLG-binding proteins were noted in the total
membrane fraction of FTLVS, all but one of which was
found in the Sarkosyl insoluble fraction (Figure 7b). The
identity of the prominent proteins from this assay (Fig-
ure 7c) are the products of the following genes:
FTL_1328 (outer membrane associated protein, fopA1),
FTL_1042 (FKBP-type peptidyl-prolyl cis-trans isomer-
ase family protein), FTL_0336 (peptidoglycan-associated
lipoprotein), FTL_0421 (hypothetical lipoprotein, lpn-A),
and FTL_0645 (hypothetical lipoprotein).
Discussion
Until recently FT has been considered an intracellular
pathogen whose dissemination to tissues distal to the
site of initial infection was highly dependent on its abil-
ity survive within host macrophages. The observation
that FT can be found in relatively high numbers in the
acellular plasma fraction of its mammalian host [15,16]
suggested that FT may have a significant extracellular
component to its life cycle and that interactions between
FT and one or more plasma proteins could contribute
to its ability to disseminate within the host. There are a
number of examples of bacterial pathogens that utilize
interactions with host plasma components to enhance
their ability to colonize and to penetrate the extracellu-
lar matrices of host cells/tissues. A wide range of bacter-
ial pathogens (including Francisella)s u b v e r tt h e
destructive mechanisms of the complement cascade by
acquiring surface-bound complement control proteins
[20,30-34]. Moreover, a number of Gram-positive bac-
terial pathogens including streptococcal spp. [35,36], sta-
phylococcal spp. [37-40], and Bacillus anthracis [41,42],
Figure 2 Purified huPLG binds to FTLVS and FTSchuS4. FTLVS
(Panel A) and FTSchuS4 (Panel B) were bound to microtiter wells
and incubated for 2 hours with purified huPLG (3 μg/ml) in the
presence or absence of 10 mM εACA). A modified ELISA was
performed to measure FTLVS-bound huPLG. The results shown are
representative of four (Panel A) and one (Panel B) experiments,
respectively, of similar design. Bars indicate +/- SEM in triplicate.
Statistical analysis was performed via one-way ANOVA using a
Dunnett’s Multiple Comparison post-test (*** P < .001).
Figure 3 εACA inhibits huPLG binding to FT in a dose-
dependent fashion. FTLVS was coated onto microtiter plate wells
and incubated for 2 hours with purified huPLG (3 μg/mL) in the
presence or absence of titrated concentrations of εACA. The results
shown are representative of 3 experiments of similar design. Bars
indicate +/- SEM in triplicate. Statistical analysis performed via one-
way ANOVA using a Kruskal-Wallis test determined a p-value of
< 0.0001.
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Page 3 of 9Figure 4 PLG binds to the outer envelope of FT. Laser scanning confocal microscopy of PLG-associated FTLVS was performed as described in
“Materials and Methods”. Bound huPLG ligand was detected using sheep anti-human PLG antibody followed by incubation with Dylight-488
conjugated donkey, anti-sheep/goat IgG secondary antibody. Samples were visualized using a Zeiss LSM 510 confocal microscope.
Figure 5 FT surface-bound huPLG can be converted to
plasmin. FTLVS was incubated with huPLG at a concentration of 96
μg/mL. After removal of unbound huPLG, a chromogenic plasmin
substrate (D-VLK-pNA), tissue PLG activator (tPA), or both were then
added to test the proteolytic ability of each sample preparation.
Conversion of the chromogenic substrate was measured by
comparison of Δ405 nm. The results shown are representative of 3
experiments of similar design. Bars indicate +/- SEM in triplicate.
Statistical analysis was performed via one-way ANOVA using a
Dunnett’s Multiple Comparison post-test (*** P < .001).
Figure 6 Fibronectin is a substrate for plasmin bound to FT.
FTLVS (10
9 CFU) were incubated with 100 μg of huPLG and 0.5 μg
tissue tPA for 1 hour at 37°C. After removal of unbound huPLG and
tPA, 3 μg fibronectin was added and allowed to incubate for 24
hours at 37°C. Supernatant from each preparation were separated
by SDS-PAGE and transferred to PVDF membrane. Degradation of
fibronectin was detected by Western blot analysis as described in
“Materials and Methods”.
Clinton et al. BMC Microbiology 2010, 10:76
http://www.biomedcentral.com/1471-2180/10/76
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aeruginosa [43] have been shown to augment their inva-
sive capacity by interacting with fibrinogen, fibronectin,
and/or PLG. Yersinia pestis is probably the best-charac-
terized example of a pathogen that exploits the host
fibrinolytic system to penetrate host tissues. Yersinia
expresses a surface serine protease (designated Pla)
whose substrates include several complement compo-
nents, PLG, and alpha2-antiplasmin (the primary circu-
lating inhibitor of plasmin). Pla also has adhesin activity
and binds to laminin (a glycoprotein of mammalian
basement membranes). Because Pla upregulates plasmin
activity, and because laminin is a substrate of plasmin,
Yersinia can very efficiently penetrate basement mem-
branes of host tissues [for review, see Suomalainen et.
al. [44]]. Clearly, interaction with plasma components is
a strategy that is used by many bacterial pathogens to
gain a survival advantage within their hosts.
The goal of the studies described here was to deter-
mine whether FT has the potential to use the host fibri-
nolytic system (specifically PLG) to enhance its ability to
penetrate/disseminate following infection of a mamma-
lian host. Our results indicate that both FTLVS and
FTSchuS4 are able to acquire surface bound PLG in
vitro and that this zymogen can be converted by a host-
derived PLG activator into its active serine protease
form (plasmin) while bound to FTLVS. The ability of
PLG to bind its ligands typically involves its lysine-bind-
ing kringle domains. This specific interaction between
PLG and exposed lysine residues can be inhibited with
the lysine-analogue εACA and, to a lesser extent, with
free lysine. Our findings revealed that binding of PLG to
the surface of FTLVS could be inhibited by εACA in a
dose-dependent fashion. Moreover, we showed that
plasmin bound to the surface of FT could degrade
fibronectin. This finding supports our hypothesis that
the ability of FT to bind to serum plasmin may enhance
its ability to penetrate extracellular matrices, enhancing
its ability to disseminate in vivo.
Using a ligand-blotting technique coupled with pro-
teomic methodologies we identified five FTLVS proteins
that were able to bind to PLG, each of which are highly
conserved among the various FT type A and B strains.
Three of these proteins are lipoproteins (gene products
of FTL_0336, FTL_0421, and FTL_0645). Two of the
lipoproteins are unique to FT, while the third, peptido-
glycan-associated lipoprotein (PAL), is highly conserved
among gram-negative bacteria. The specific use of sur-
face-exposed lipoproteins as receptors for host PLG is
not unusual and has been well documented in other
human bacterial pathogens, such as some members of
the genus Borrelia and Treponema. Several members of
the genus Borrelia use complement regulator-acquiring
surface proteins (CRASP) to bind both PLG and com-
plement factor H to aid in the ability of the organism to
both disseminate and to resist innate immunity [45-50].
An additional example of a PLG-binding lipoprotein is
OppA of Treponema denticola, which has been sug-
gested to play a role in periodontal disease in humans
[51]. With this in mind, there lies the possibility that
lipoproteins of Francisella species may have the capacity
to bind multiple host-derived proteins in addition to
PLG.
Here we have shown that FT can bind to PLG and
that surface-bound PLG can be activated by tPA to its
proteolytic form (plasmin). The binding of PLG on the
surface of FT could play a role in several phases of
tularemia, including the initial entry into the host
through insect bites and/or broken skin where active
fibrinolytic processes would provide an early
Figure 7 Identification of putative PLG-binding proteins of FT. Sarkosyl-soluble and insoluble protein fractions of FTLVS were separated by
SDS-PAGE and transferred to PVDF membrane. Membranes were then blotted with huPLG (3 ug/mL) followed by anti-PLG antibody and HRP-
conjugated secondary antibody to detect PLG-binding proteins (Panel A). Protein bands on an identical Coomassie Blue-stained SDS-PAGE gel
corresponding to those identified via blotting (Panel B) were excised and identified using proteomic methodologies (Panel C).
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might augment the establishment or dissemination of
infection. During later phases of tularemia the acquisi-
tion of plasmin on the cell surface may contribute to its
pathogenicity by degrading host innate effector mole-
cules and extracellular matrix components. Based on the
new report that FT-bound plasmin can degrade immu-
noglobulins [52], as well as the established ability of FT
to acquire surface-bound factor H [20], it also appears
likely that FT uses plasma components to interfere with
host humoral immune mechanisms throughout the
course of FT infection. Future studies to identify addi-
tional plasma components that can be surface acquired
by FT may uncover additional virulence mechanisms
used by this pathogen during its extracellular life cycle.
Conclusions
FT interacts with at least two serum components (plas-
min, and complement factor H), and it seems likely that
FT also uses interactions with additional host serum
components to gain a survival advantage. Our lab is
examining FT interactions with additional targets,
including fibrinogen and fibronectin, both of which are
substrates for plasmin and are host components that are
known to be exploited by numerous pathogens for adhe-
sion to and penetration of extracellular matrix layers.
The interaction of FT with host serum components may
play a significant role in the survival and dissemination
of this highly pathogenic bacterium. Gaining a better
understanding of these interactions could be a critical
step in the development of therapeutic and prophylactic
interventions for tularemic disease.
Methods
Bacterial strains and culture
F. tularensis Live Vaccine Strain (FTLVS) was a kind gift
of Dr. Karen Elkins (FDA, Bethesda, MD). FT Schu S4
was obtained from the CDC. All bacterial cultures were
grown overnight in Brain-Heart Infusion broth (37 g/L,
pH 6.8) from frozen stocks at 37°C with shaking to mid-
log phase (OD600 = ~0.7) before use.
Reagents
Human fresh frozen plasma (FFP) was purchased from
Lifeblood Mid-South Regional Blood Center (Memphis,
TN). Purified human Glu-PLG (huPLG), human single-
chain tissue PLG activator (tPA), and the plasmin
colorimetric substrate (H-D-Val-Leu-Lys-pNA) were
purchased from Molecular Innovations (Novi, MI).
Bovine serum albumin (fraction V) was purchased from
Thermo-Fisher Scientific (Pittsburgh, PA). Polyclonal
sheep anti-human PLG, anti-human fibronectin, and
donkey anti-sheep/goat IgG:Dylight-488 antibody pre-
parations purchased from AbD Serotec (Raleigh, NC).
Monoclonal anti-goat/sheep IgG-horseradish peroxidase
conjugated secondary antibody (clone GT-34) and
ε-aminocaproic acid (A7824) were purchased from
Sigma-Aldrich (St. Louis, MO). Ninety-six well MAXI-
SORP ELISA plates were purchased from Nunc (Roche-
ster, NY).
PLG binding ELISA assays
FTLVS was cultured overnight to mid-log phase, pelleted
at 6,400 × g for 30 minutes, washed twice with phos-
phate-buffered saline (PBS), and resuspended in PBS
with 0.1% Na azide to an OD600 = 0.1. The resulting bac-
terial suspension was added to microtiter plates (100 μL/
well; approximately 2.5 × 10
8 bacterial cells) before being
incubated overnight at 4°C to facilitate binding. The wells
were then washed twice with 200 μL of Tris-buffered sal-
ine (TBS) pH 7.45 containing 0.05% Tween-20 (TBST) to
remove unbound bacteria and then pre-blocked with 200
μL of TBST containing 1% bovine serum albumin (1%
BSA-TBST) for 1 hour at RT° to prevent non-specific
protein binding. After removal of the blocking solution,
90% citrated human plasma or 3 μg/mL huPLG in 1%
BSA-TBST was added to each well (100 μL), with or
without the indicated concentrations of ε-amino caproic
acid (εACA), and incubated for 1-2 hours at 37°C with
gentle rocking. Wells were washed three times with
TBST and then sheep anti-human PLG-specific antibody
(1:2,000 dilution in 1% BSA-TBST) was added (100 μL/
well) and allowed to incubate for 1 hour at 37°C.
Unbound primary antibodies were removed by washing
three times with TBST, followed by the addition of HRP-
conjugated anti-sheep/goat IgG mAb (GT-34, 1:5,000
dilution in 1% BSA-TBST; 100 μL/well) and incubation
for 1 hour at 37°C. Unbound secondary antibodies were
removed by washing four times with TBST, and OptEIA
TMB colorimetric substrate solution (Becton-Dickenson,
Franklin Lakes, NJ) was added to each well (100 μL/well)
and incubated at 37°C for 20 min. to allow color develop-
ment. Absorbance at 450 nm was determined using a
SpectraMAX 340 plate reader (Molecular Devices, Sun-
nyvale, CA).
Indirect immunofluorescence assays
FTLVS was cultured and washed as described above.
After diluting the washed bacteria to OD600 =0 . 1 ,1m L
aliquots were incubated with a total of 40 μgs of PLG or
PBS (negative control) for 30 minutes at 37°C with gen-
tle rotation. Bacteria were then washed three times with
PBS by centrifugation, resuspended in 100 μLo fP B S ,
followed by spotting 20 μLo fe a c hs a m p l eo n t og l a s s
coverslips. The samples were then air-dried overnight at
37°C. After methanol fixation, the coverslips were
blocked with 1% BSA-PBS at room temperature before
adding sheep anti-human PLG (1:100 diluted in 1%
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coverslips were gently washed with PBS before adding
donkey anti-sheep/goat IgG:Dylight-488 (1:100 diluted
in 1% BSA-PBS), followed by incubation for 30 minutes
at room temperature. After washing again with PBS,
coverslips were mounted onto glass slides using 100%
glycerol containing 0.1 M n-propyl gallate and images
were collected on a Zeiss LSM 510 confocal microscope
with an Axiovert 100 M base with a 100× Plan Apoc-
hromat 1.4 NA oil DIC objective using the argon laser
for 488 nm excitation and 505-530 nm bandpass emis-
sion filter for imaging Dylight488 fluorescence and the
HeNe1 543 nm laser for illumination of the DIC images.
Both images were collected using identical detector gain
and amplifier offset settings, and the images shown are
1.0 μm optical slices. Digital images were visualized
using Zeiss AxioVision LE software.
Chromogenic plasmin activation assay
FTLVS was cultured overnight to mid-log phase, washed
twice with TBS and then resuspended in TBS to an
OD600 of 0.7. Aliquots of the bacterial suspension
(50 μL) was added to 50 μL of TBS alone or TBS con-
taining huPLG (192 μg/mL) and incubated for 1 hour at
37°C. The cells were washed 3× with TBST containing
0.1% BSA, and pellets were resuspended in 200 μLo f
TBS and then split into two 100 μLa l i q u o t s .5 0μLo f
50 mM Tris-HCl (pH 7.45) with or without 333 μMo f
the chromogenic plasmin substrate (H-D-Val-Leu-Lys-
pNA) and 50 μL1 . 2μg of tPA or TBS alone was added
to each sample and incubated at 37°C for 3 h. Bacteria
were pelleted via centrifugation and 150 μL of each
supernatant was pipetted into a 96-well plate and absor-
b a n c ea t4 0 5n mw a sd e t e r m i n e da sam e a s u r eo fp l a s -
min activity.
Membrane protein fractionation
Outer membrane enriched fractions were isolated by a
procedure adapted from de Bruin, et al [53]. FTLVS
were grown in BHI broth (500 ml) to mid-log phase and
then were pelleted via centrifugation at 6,400 × g for 30
minutes. Cells were resuspended in cold PBS and then
lysed by sonication. Unlysed bacterial cells were sepa-
rated from the whole-cell lysate by centrifugation at
10,000 × g for 20 minutes at 4°C. The insoluble mem-
brane fraction was then isolated by ultracentrifugation
for 1 hour at 100,000 × g at 4°C. After removal of the
soluble protein fraction, the pelleted total membrane
fraction was resuspended in 1% sarkosyl with vortexing
and subjected to a second round of ultracentrifugation
for 1 hour at 100,000 × g at 4°C. The Sarkosyl-insoluble
pellet was resuspended in 50 mM Tris pH 8. The pro-
tein concentration of both the Sarkosyl-soluble and Sar-
kosyl-insoluble fractions was determined using the DC
protein assay (Bio-Rad, Hercules, CA) according to
manufacturer directions. Samples were stored at -20°C
until use.
Fibronectin degradation assay
Overnight cultures of FTLVS were washed three times
with PBS, 10
9 CFU were pipetted into 1.5 mL tubes, and
bacteria were pelleted via centrifugation at 18,900 × g
for 10 minutes. Bacterial pellets were then resuspended
in 50 μl of PBS with or without PLG (2 mg/ml), fol-
lowed by the addition of 50 μlo ft P A( 1 0μg/mL) and
incubation at 37°C with gentle shaking for 1 hour. The
bacterial suspensions were pelleted via centrifugation at
18,900 × g, washed 3× with PBS and resuspended with
100 μl of 50 mM Tris, 100 mM NaCl, 5 mM CaCl2)
with 3 μg fibronectin (BD Biosciences) and incubation
at 37°C with gentle shaking for 24 hours. After the incu-
bation was complete, bacteria were pelleted via centrifu-
gation at 18,900 × g and the supernatants were
solublized by boiling in 2× SDS-PAGE sample buffer
containing 2-mercaptoethanol. Samples were subjected
to 10% SDS-PAGE and then electrophoretically trans-
ferred to a PVDF membrane (Immobilon-P, Millipore).
T h eP V D Fm e m b r a n ew a sp r e - b l o c k e dw i t h1 %B S A -
TBST for 1 hour at RT to minimize non-specific protein
binding, and was then incubated with sheep anti-human
fibronectin-specific antibody (diluted 1:2000 in 1% BSA-
TBST) for 1 hour at RT with gentle rocking. The PVDF
membrane was washed three times with TBST to
remove unbound primary antibody. The membrane was
then incubated in a solution of anti-sheep/goat IgG
monoclonal antibody (GT-34, diluted 1:5000 in 1%BSA-
TBST) with rocking for 1 hr at RT. The PVDF mem-
branes were washed 3 times with TBST to remove
unbound secondary antibody. The blot was developed
using Pierce PicoWest chemiluminescence reagents and
images were captured using a Bio-Rad ChemiDoc XRS
system.
Far-Western blotting analysis
Approximately 100 μg of each protein fraction was pre-
cipitated using ice-cold acetone, pelleted via centrifuga-
tion at 18,900 × g for 15 minutes, and air-dried at room
temperature. The samples were then solublized by boil-
ing in 1× SDS-PAGE sample buffer containing 2-mer-
captoethanol. Duplicate 20 μLa l i q u o t so fe a c hs a m p l e
were subjected to 15% SDS-PAGE to separate the pro-
teins based on their size. One set of the samples was
then electrophoretically transferred to a PVDF mem-
brane (Immobilon-Psq, Millipore). The PVDF mem-
brane was pre-blocked with 1% BSA-TBST for 1 hour at
room temperature to minimize non-specific protein
binding and was then incubated in a solution of huPLG
(3 ug/mL in 1% BSA-TBST) for one hour with rocking
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times with TBST. Sheep anti-human PLG-specific anti-
body (diluted 1:2,000 in 1% BSA-TBST) was added
(100 μL/well) and allowed to incubate for 1 hour at RT°
with rocking. The PVDF membrane was washed three
times with TBST to remove unbound primary antibody.
The membrane was then incubated in a solution of
anti-sheep/goat IgG monoclonal antibody (GT-34,
diluted 1:5,000 in 1%BSA-TBST) with rocking for 1 hr
at room temperature. The PVDF membranes were
washed three times with TBST to remove unbound sec-
ondary antibody. The blot was developed using Pierce
PicoWest chemiluminescence reagents and imaged
using a Bio-Rad ChemiDoc XRS system.
Proteomic identification of PLG-binding FT proteins
Protein bands were excised from Coomassie-stained
SDS-PAGE gels, cut into small pieces, incubated in 50%
acetonitrile/100 mM ammonium bicarbonate until col-
orless, and dried via vacuum centrifugation. The protein
was digested by adding 20 μl of a 20 ng/μl trypsin solu-
tion and incubating overnight at 37°C. Peptides were
extracted from the gel slices via sonication in 50 μl 60%
acetonitrile/5%TFA, dried via vacuum centrifugation,
and reconstituted in 15 μl 0.1% TFA. Tryptic peptides
were desalted/enriched using a C18 ZipTip column
(Millipore, Billerica, MA) according to manufacturer’s
instructions and the eluant was spotted on a MALDI
plate and dried. Samples were analyzed using a
MALDI-LTQ mass spectrometer (ThermoFinnigan, San
Jose, CA). A full MS scan in high-mass range (m/z 600-
4000, 5 microscans) was performed. The 50 most
intense peaks in the full MS spectrum were selected,
and MSMS scans were performed for those ions in
high-mass range (m/z 50-4000, 5 microscans), the nor-
malized collision energy for MSMS was 35. Xcalibur
software was used to process the mass spectrometric
data, and the NCBInr database and the Bioworks 3.2
search engine software were used for database
searching.
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